(17)Non-Controlling Interests
Details of non-controlling interests and movement at 31 December 2016 are as follows:
|
|
|
Thousands of Euros |
|
||||||||||
|
|
|
Balance at |
|
Additions |
|
Disposals |
|
Capital increases |
|
Translation |
|
Balance at |
|
|
Grifols (Thailand) Pte Ltd |
|
2,664 |
|
778 |
|
(215 |
) |
— |
|
127 |
|
3,354 |
|
|
Grifols Malaysia Sdn Bhd |
|
1,040 |
|
144 |
|
— |
|
— |
|
(12 |
) |
1,172 |
|
|
Araclon Biotech, S.A. |
|
183 |
|
(1,819 |
) |
— |
|
1,776 |
|
— |
|
140 |
|
|
Medion Grifols Diagnostic AG |
|
(406 |
) |
— |
|
406 |
|
— |
|
— |
|
— |
|
|
GRI-CEI S/A Productos para transfusao |
|
1,146 |
|
— |
|
(1,146 |
) |
— |
|
— |
|
— |
|
|
Progenika Biopharma, S.A. |
|
1,093 |
|
165 |
|
— |
|
— |
|
(47 |
) |
1,211 |
|
|
Brainco Biopharma, S.L. |
|
(373 |
) |
— |
|
373 |
|
— |
|
— |
|
— |
|
|
Abyntek Biopharma, S.L. |
|
(93 |
) |
20 |
|
— |
|
— |
|
— |
|
(73 |
) |
|
VCN Bioscience, S.L |
|
(67 |
) |
(201 |
) |
— |
|
961 |
|
— |
|
693 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,187 |
|
(913 |
) |
(582 |
) |
2,737 |
|
68 |
|
6,497 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(see note 2(b)) |
|
|
|
|
|
|
|
Details of non-controlling interests and movement at 31 December 2017 are as follows:
|
|
|
Thousands of Euros |
|
||||||||||
|
|
|
Balance at |
|
Additions |
|
Disposals |
|
Business |
|
Translation |
|
Balance at |
|
|
Grifols (Thailand) Pte Ltd |
|
3,354 |
|
433 |
|
(77 |
) |
— |
|
(131 |
) |
3,579 |
|
|
Grifols Malaysia Sdn Bhd |
|
1,172 |
|
229 |
|
— |
|
— |
|
(29 |
) |
1,372 |
|
|
Araclon Biotech, S.A. |
|
140 |
|
(1,617 |
) |
— |
|
— |
|
— |
|
(1,477 |
) |
|
Progenika Biopharma, S.A. |
|
1,211 |
|
(60 |
) |
(297 |
) |
— |
|
27 |
|
881 |
|
|
Abyntek Biopharma, S.L. |
|
(73 |
) |
45 |
|
28 |
|
— |
|
— |
|
— |
|
|
VCN Bioscience, S.L |
|
693 |
|
(272 |
) |
— |
|
— |
|
— |
|
421 |
|
|
Kiro Grifols , S.L. |
|
— |
|
(144 |
) |
— |
|
254 |
|
— |
|
110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,497 |
|
(1,386 |
) |
(346 |
) |
254 |
|
(133 |
) |
4,886 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|